Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Rudick, Richard A ^a   Rani, M R Sandhya ^a   Xu, Yaomin ^a   Lee, Jar Chi ^a   Na, Jie ^a   Shrock, Jennifer ^a   Josyula, Anupama ^a   Fisher, Elizabeth ^a   Ransohoff, Richard M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; BIOLOGICAL MARKER; COMPLEMENTARY DNA; BETA INTERFERON;

ADULT; ARTICLE; DRUG RESPONSE; FEMALE; GENE INDUCTION; HUMAN; INNATE IMMUNITY; INTERFERON REGULATED GENE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PROGNOSIS; REGULATOR GENE; BRAIN; CLINICAL TRIAL; DNA MICROARRAY; DRUG EFFECT; GENETICS; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; TIME; TREATMENT OUTCOME; UPREGULATION;

ADULT; BRAIN; FEMALE; HUMANS; IMMUNITY, INNATE; INTERFERON-BETA; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 79955943425     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019262     Document Type: Article

References (49)

1. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. the multiple sclerosis collaborative research group (MSCRG). Ann Neurol 39: 285-294.
2. PRISMS (prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) study group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352: 1498-1504.
3. The IFNB multiple sclerosis study group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655-661.
4. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E, (2004) Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56: 548-555.
5. Rio J, Rovira A, Tintore M, Huerga E, Nos C, et al. (2008) Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler 14: 479-484.
6. Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, et al. (2008) MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. J Neurol Neurosurg Psychiatr 79: 646-651.
7. Prosperini L, Gallo V, Petsas N, Borriello G, Pozzilli C, (2009) One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 16: 1202-1209.
8. Panitch HS, Hirsch RL, Haley AS, Johnson KP, (1987) Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1: 893-895.
9. Panitch HS, Hirsch RL, Schindler J, Johnson KP, (1987) Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system. Neurology 37: 1097-1102.
10. Banchereau J, Pascual V, (2006) Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25 (3): 383-392.
11. van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, Baggen JM, Rustenburg F, et al. (2006) A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 7: 522-531.
12. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, et al. (2010) T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16: 406-412.
13. Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ, (2007) Lesion genesis in a subset of patients with multiple sclerosis: A role for innate immunity? Brain130(Pt 11): 2800-2815.
14. Bertolotto A, Gilli F, (2008) Interferon-beta responders and non-responders. A biological approach. Neurol Sci 29 (Suppl 2): S216-7.
15. Sbardella E, Tomassini V, Gasperini C, Bellomi F, Cefaro LA, et al. (2009) Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: A retrospective study. BMC Neurol 9: 54.
16. Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, et al. (2003) Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain126(Pt 6): 1419-1429.
17. Wandinger KP, Sturzebecher CS, Bielekova B, Detore G, Rosenwald A, et al. (2001) Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 50 (3): 349-357.
18. Kurtzke JF, (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33: 1444-1452.
19. Rudick RA, Cutter G, Reingold S, (2002) The multiple sclerosis functional composite: A new clinical outcome measure for multiple sderosis trials. Mult Scler 8: 359-365.
20. Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, et al. (1999) Cerebrospinal fluid abnormalities in a phase III trial of avonex (IFNbeta-1a) for relapsing multiple sclerosis. The multiple sclerosis collaborative research group. J Neuroimmunol 932): 8-14.
21. Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, et al. (2008) Avonex combination trial in relapsing--remitting MS: Rationale, design and baseline data. Mult Scler 14: 370-382.
22. Rani MR, Xu Y, Lee JC, Shrock J, Josyula A, et al. (2009) Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta. Ann N Y Acad Sci 1182: 58-68.
23. Schlaak JF, Hilkens CM, Costa-Pereira AP, Strobl B, Aberger F, et al. (2002) Cell-type and donor-specific transcriptional responses to interferon-alpha. Use of customized gene arrays. J Biol Chem 277: 49428-49437.
24. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, et al. (2007) Interferons at age 50: Past, current and future impact on biomedicine. Nat Rev Drug Discov 6: 975-990.
25. Wandinger KP, Lunemann JD, Wengert O, Bellmann-Strobl J, Aktas O, et al. (2003) TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 361 (9374): 2036-2043.
26. Reder AT, Velichko S, Yamaguchi KD, Hamamcioglu K, Ku K, et al. (2008) IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res 28: 317-331.
27. Kauffman MA, Yankilevich P, Barrero P, Bello R, Marangunich L, et al. (2009) Whole genome analysis of the action of interferon-beta. Int J Clin Pharmacol Ther 47: 328-357.
28. Sturzebecher S, Maibauer R, Heuner A, Beckmann K, Aufdembrinke B, (1999) Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers. J Interferon Cytokine Res 19: 1257-1264.
29. Kantor AB, Deng J, Waubant E, Lin H, Becker CH, et al. (2007) Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling. J Neuroimmunol 188: 103-116.
30. Prync AE, Yankilevich P, Barrero PR, Bello R, Marangunich L, et al. (2008) Two recombinant human interferon-beta 1a pharmaceutical preparations produce a similar transcriptional response determined using whole genome microarray analysis. Int J Clin Pharmacol Ther 46: 64-71.
31. Wenink MH, Santegoets KC, Broen JC, van Bon L, Abdollahi-Roodsaz S, et al. (2009) TLR2 promotes Th2/Th17 responses via TLR4 and TLR7/8 by abrogating the type I IFN amplification loop. J Immunol 183: 6960-6970.
32. Naundorf S, Schroder M, Hoflich C, Suman N, Volk HD, et al. (2009) IL-10 interferes directly with TCR-induced IFN-gamma but not IL-17 production in memory T cells. Eur J Immunol 39: 1066-1077.
33. van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, et al. (2008) Pharmacogenomics of interferon-beta therapy in multiple sclerosis: Baseline IFN signature determines pharmacological differences between patients. PLoS ONE 3: e1927.
34. Comabella M, Lunemann JD, Rio J, Sanchez A, Lopez C, et al. (2009) A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain132(Pt 12): 3353-3365.
35. De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, et al. (2009) Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 41: 776-782.
36. Ban M, Goris A, Lorentzen AR, Baker A, Mihalova T, et al. (2009) Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet 17: 1309-1313.
37. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105: 7034-7039.
38. Drulovic J, Savic E, Pekmezovic T, Mesaros S, Stojsavljevic N, et al. (2009) Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: Does baseline T-bet mRNA predict the response to interferon-beta treatment? J Neuroimmunol 215: 90-95.
39. Zhang X, Jin J, Tang Y, Speer D, Sujkowska D, et al. (2009) IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J Immunol 182: 3928-3936.
40. Buttmann M, Merzyn C, Hofstetter HH, Rieckmann P, (2007) TRAIL, CXCL10 and CCL2 plasma levels during long-term interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. J Neuroimmunol 190: 170-176.
41. Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, et al. (2008) Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 70(13 Pt 2): 1119-1127.
42. Wiesemann E, Deb M, Hemmer B, Radeke HH, Windhagen A, (2008) Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clin Immunol 128: 306-313.
43. Carrieri PB, Ladogana P, Di Spigna G, de Leva MF, Petracca M, et al. (2008) Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: Differences in responders and non responders. Immunopharmacol Immunotoxicol 30: 1-9.
44. Gandhi KS, McKay FC, Schibeci SD, Arthur JW, Heard RN, et al. (2008) BAFF is a biological response marker to IFN-beta treatment in multiple sclerosis. J Interferon Cytokine Res 28: 529-539.
45. Goertsches RH, Hecker M, Zettl UK, (2008) Monitoring of multiple sclerosis immunotherapy: From single candidates to biomarker networks. J Neurol 255 (Suppl 6): 48-57.
46. Garcia-Merino A, Barcenilla H, Diaz D, Monserrat J, Prieto A, et al. (2009) IFNbeta therapy progressively normalizes the increased ex vivo T lymphocyte apoptosis observed in active patients with multiple sclerosis. Clin Immunol 132: 195-202.
47. Sellebjerg F, Krakauer M, Hesse D, Ryder LP, Alsing I, et al. (2009) Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur J Neurol 16: 1291-1298.
48. Mameli G, Serra C, Astone V, Castellazzi M, Poddighe L, et al. (2008) Inhibition of multiple-sclerosis-associated retrovirus as biomarker of interferon therapy. J Neurovirol 14: 73-77.
49. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, et al. (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338: 278-285.